Sarepta Therapeutics (SRPT) Tops Q1 EPS by 23c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Crypto stocks rise premarket as Bitcoin hits over seven-month high
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- FortuneX and WT Realty announce $600M merger deal
Sarepta Therapeutics Announces First Quarter 2021 Financial Results and Recent Corporate Developments
May 5, 2021 4:05 PM EDTNet product sales for the first quarter 2021 of $124.9 million, a 24% increase over the same quarter of prior year
CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter of 2021.
In the first quarter, we obtained FDA approval for and launched our third RNA therapy for Duchenne, AMONDYS 45 (casimersen). The first AMONDYS 45 patient was treated within the first week of approval. Serving the community... More
